Katherine M Newton1, Janet S Carpenter, Katherine A Guthrie, Garnet L Anderson, Bette Caan, Lee S Cohen, Kristine E Ensrud, Ellen W Freeman, Hadine Joffe, Barbara Sternfeld, Susan D Reed, Sheryl Sherman, Mary D Sammel, Kurt Kroenke, Joseph C Larson, Andrea Z Lacroix. 1. From the 1Group Health Research Institute, Seattle, WA; 2School of Nursing, Indiana University, Indianapolis, IN; 3Data Coordinating Center, Fred Hutchinson Cancer Research Center, Seattle, WA; 4Division of Research, Kaiser Permanente of Northern California, Oakland, CA; 5Massachusetts General Hospital/Harvard Medical School, Boston, MA; 6VA Medical Center/University of Minnesota, Minneapolis, MN; 7Departments of Obstetrics/Gynecology and Psychiatry, University of Pennsylvania School of Medicine, Philadelphia, PA; 8Department of Obstetrics/Gynecology and Department of Epidemiology, School of Public Health and Community Medicine, University of Washington, Seattle, WA; 9National Institute on Aging, US National Institutes of Health, Bethesda, MD; 10Center for Clinical Epidemiology and Statistics, University of Pennsylvania School of Medicine, Philadelphia, PA; and 11VA Center of Excellence for Implementing Evidence-Based Practice and Indiana University School of Medicine, Indianapolis, IN.
Abstract
OBJECTIVE: This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials. METHODS: Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms. Included are descriptions of and rationale for criteria used for interventions and study selection, common eligibility and exclusion criteria, common primary and secondary outcome measures, consideration of placebo response, establishment of a biorepository, trial duration, screening and recruitment, statistical methods, and quality control. All trial designs are presented, including the following: (1) a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of the selective serotonin reuptake inhibitor escitalopram in reducing vasomotor symptom frequency and severity; (2) a two-by-three factorial design trial to test three different interventions (yoga, exercise, and ω-3 supplementation) for the improvement of vasomotor symptom frequency and bother; and (3) a three-arm comparative efficacy trial of the serotonin-norepinephrine reuptake inhibitor venlafaxine and low-dose oral estradiol versus placebo for reducing vasomotor symptom frequency. The network's structure and governance are also discussed. CONCLUSIONS: The methods used in and the lessons learned from the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health trials are shared to encourage and support the conduct of similar trials and to encourage collaborations with other researchers.
OBJECTIVE: This report describes the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network and methodological issues addressed in designing and implementing vasomotor symptom trials. METHODS: Established in response to a National Institutes of Health request for applications, the network was charged with conducting rapid throughput randomized trials of novel and understudied available interventions postulated to alleviate vasomotor and other menopausal symptoms. Included are descriptions of and rationale for criteria used for interventions and study selection, common eligibility and exclusion criteria, common primary and secondary outcome measures, consideration of placebo response, establishment of a biorepository, trial duration, screening and recruitment, statistical methods, and quality control. All trial designs are presented, including the following: (1) a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effectiveness of the selective serotonin reuptake inhibitor escitalopram in reducing vasomotor symptom frequency and severity; (2) a two-by-three factorial design trial to test three different interventions (yoga, exercise, and ω-3 supplementation) for the improvement of vasomotor symptom frequency and bother; and (3) a three-arm comparative efficacy trial of the serotonin-norepinephrine reuptake inhibitor venlafaxine and low-dose oral estradiol versus placebo for reducing vasomotor symptom frequency. The network's structure and governance are also discussed. CONCLUSIONS: The methods used in and the lessons learned from the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health trials are shared to encourage and support the conduct of similar trials and to encourage collaborations with other researchers.
Authors: Luciane de Souza; Ana Amélia Benedito-Silva; Maria Laura Nogueira Pires; Dalva Poyares; Sergio Tufik; Helena Maria Calil Journal: Sleep Date: 2003-02-01 Impact factor: 5.849
Authors: Janet S Carpenter; Anna Maria Storniolo; Shelley Johns; Patrick O Monahan; Faouzi Azzouz; Julie L Elam; Cynthia S Johnson; Richard C Shelton Journal: Oncologist Date: 2007-01
Authors: Sandhya Pruthi; Rui Qin; Shelby A Terstreip; Heshan Liu; Charles L Loprinzi; Tushar R C Shah; Kenneth F Tucker; Shaker R Dakhil; Martin J Bury; Robert L Carolla; Preston D Steen; Jacqueline Vuky; Debra L Barton Journal: Menopause Date: 2012-01 Impact factor: 2.953
Authors: Ellen W Freeman; Katherine A Guthrie; Bette Caan; Barbara Sternfeld; Lee S Cohen; Hadine Joffe; Janet S Carpenter; Garnet L Anderson; Joseph C Larson; Kristine E Ensrud; Susan D Reed; Katherine M Newton; Sheryl Sherman; Mary D Sammel; Andrea Z LaCroix Journal: JAMA Date: 2011-01-19 Impact factor: 157.335
Authors: Janet S Carpenter; Katherine M Newton; Barbara Sternfeld; Hadine Joffe; Susan D Reed; Kristine E Ensrud; Jennifer L Milata Journal: Menopause Date: 2012-06 Impact factor: 3.310
Authors: Caroline M Mitchell; Sujatha Srinivasan; Anna Plantinga; Michael C Wu; Susan D Reed; Katherine A Guthrie; Andrea Z LaCroix; Tina Fiedler; Matthew Munch; Congzhou Liu; Noah G Hoffman; Ian A Blair; Katherine Newton; Ellen W Freeman; Hadine Joffe; Lee Cohen; David N Fredricks Journal: Menopause Date: 2018-05 Impact factor: 2.953
Authors: Janet S Carpenter; James E Tisdale; Joseph C Larson; Ying Sheng; Chen X Chen; Diane Von Ah; Richard Kovacs; Susan D Reed; Rebecca C Thurston; Katherine A Guthrie Journal: Menopause Date: 2021-11-29 Impact factor: 2.953
Authors: Susan D Reed; Andrea Z LaCroix; Garnet L Anderson; Kristine E Ensrud; Bette Caan; Janet S Carpenter; Lee Cohen; Susan J Diem; Ellen W Freeman; Hadine Joffe; Joseph C Larson; Susan M McCurry; Caroline M Mitchell; Katherine M Newton; Barbara Sternfeld; Katherine A Guthrie Journal: Menopause Date: 2020-04 Impact factor: 2.953
Authors: Salene M W Jones; Katherine A Guthrie; Andrea Z LaCroix; Barbara Sternfeld; Carol A Landis; Susan D Reed; Andrea Dunn; Bette Caan; Lee S Cohen; Julie Hunt; Katherine M Newton Journal: Clin Auton Res Date: 2015-12-21 Impact factor: 5.625
Authors: Laura López-Ríos; Miguel A Barber; Julia Wiebe; Rubén P Machín; Tanausú Vega-Morales; Ricardo Chirino Journal: PLoS One Date: 2021-07-21 Impact factor: 3.240
Authors: Katherine A Guthrie; Andrea Z LaCroix; Kristine E Ensrud; Hadine Joffe; Katherine M Newton; Susan D Reed; Bette Caan; Janet S Carpenter; Lee S Cohen; Ellen W Freeman; Joseph C Larson; JoAnn E Manson; Kathy Rexrode; Todd C Skaar; Barbara Sternfeld; Garnet L Anderson Journal: Obstet Gynecol Date: 2015-08 Impact factor: 7.623
Authors: S D Reed; K M Newton; J C Larson; C Booth-LaForce; N F Woods; C A Landis; E Tolentino; J S Carpenter; E W Freeman; H Joffe; B D Anawalt; K A Guthrie Journal: Clin Endocrinol (Oxf) Date: 2016-01-26 Impact factor: 3.523